Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.

Adult Aged Anaplastic Lymphoma Kinase / antagonists & inhibitors Antineoplastic Combined Chemotherapy Protocols / adverse effects Cisplatin / administration & dosage Docetaxel / administration & dosage Female Head and Neck Neoplasms / drug therapy High-Throughput Nucleotide Sequencing Humans Male Middle Aged Neoplasm Recurrence, Local / drug therapy
Cisplatin Docetaxel Non-squamous-cell head and neck cancer Phase II trial

Journal

Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512

Informations de publication

Date de publication:
22 Sep 2021
Historique:
received: 17 08 2021
accepted: 12 09 2021
entrez: 22 9 2021
pubmed: 23 9 2021
medline: 8 2 2022
Statut: epublish

Résumé

The clinical utility of systemic therapy and genomic profiling in non-squamous-cell head and neck cancer (NSCHNC) has not been fully elucidated. This phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination in the first-line setting. Eligibility criteria were recurrent and/or metastatic NSCHNC; progressive disease within the last 6 months; no prior systemic therapy; and ECOG performance status of 0-1. Patients received docetaxel (75 mg/m

Identifiants

DOI: 10.1007/s12032-021-01581-z PMID: 34550483
pubmed: 34550483
doi: 10.1007/s12032-021-01581-z
pii: 10.1007/s12032-021-01581-z
doi:

Substances chimiques

Docetaxel 15H5577CQD
ALK protein, human EC 2.7.10.1
Anaplastic Lymphoma Kinase EC 2.7.10.1
Cisplatin Q20Q21Q62J

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

128

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology, Japan
ID : 26462605
Organisme : Ministry of Education, Culture, Sports, Science and Technology, Japan
ID : 17K11384

Informations de copyright

© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48. https://doi.org/10.1001/jamaoncol.2016.5688 .
doi: 10.1001/jamaoncol.2016.5688 pubmed: 27918777
Network NCC. NCCN Guidelines® for Head and Neck Cancers, version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . Accessed 26 March 2021.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27. https://doi.org/10.1056/NEJMoa0802656 .
doi: 10.1056/NEJMoa0802656 pubmed: 18784101
Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7:640–2. https://doi.org/10.1093/oxfordjournals.annonc.a010684 .
doi: 10.1093/oxfordjournals.annonc.a010684 pubmed: 8879381
Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987;5:951–5. https://doi.org/10.1200/JCO.1987.5.6.951 .
doi: 10.1200/JCO.1987.5.6.951 pubmed: 3585449
Dimery IW, Legha SS, Hong WK, et al. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol. 1990;8:1056–62. https://doi.org/10.1200/JCO.1990.8.6.1056 .
doi: 10.1200/JCO.1990.8.6.1056 pubmed: 2112183
Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91:541–7. https://doi.org/10.1002/1097-0142(20010201)91:3%3c541::aid-cncr1032%3e3.0.co;2-y .
doi: 10.1002/1097-0142(20010201)91:3<541::aid-cncr1032>3.0.co;2-y pubmed: 11169936
Airoldi M, Garzaro M, Pedani F, et al. Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases. Am J Clin Oncol. 2017;40:86–90. https://doi.org/10.1097/COC.0000000000000112 .
doi: 10.1097/COC.0000000000000112 pubmed: 25089531
Hong MH, Kim CG, Koh YW, et al. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018;40:55–62. https://doi.org/10.1002/hed.24933 .
doi: 10.1002/hed.24933 pubmed: 29044862
Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562–7. https://doi.org/10.1200/JCO.2005.01.057 .
doi: 10.1200/JCO.2005.01.057 pubmed: 15908667
Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol. 2000;11:845–9. https://doi.org/10.1023/a:1008355315205 .
doi: 10.1023/a:1008355315205 pubmed: 10997812
Gedlicka C, Formanek M, Selzer E, et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology. 2002;63:145–50. https://doi.org/10.1023/a:1008355315205 .
doi: 10.1023/a:1008355315205 pubmed: 12239449
Glisson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002;20:1593–9. https://doi.org/10.1200/JCO.2002.20.6.1593 .
doi: 10.1200/JCO.2002.20.6.1593 pubmed: 11896109
Caponigro F, Massa E, Manzione L, et al. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol. 2001;12:199–202. https://doi.org/10.1023/a:1008322415335 .
doi: 10.1023/a:1008322415335 pubmed: 11300324
Chang PM, Tzeng CH, Chen MH, et al. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer Chemother Pharmacol. 2011;68:1477–84. https://doi.org/10.1007/s00280-011-1645-5 .
doi: 10.1007/s00280-011-1645-5 pubmed: 21484308
Nakano K, Sato Y, Sasaki T, et al. Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol. 2016;136:948–51. https://doi.org/10.3109/00016489.2016.1170876 .
doi: 10.3109/00016489.2016.1170876 pubmed: 27094013
Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2000;20:3781–3.
pubmed: 11268454
Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer. 2010;116:362–8. https://doi.org/10.1002/cncr.24745 .
doi: 10.1002/cncr.24745 pubmed: 19924794
Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50:683–90. https://doi.org/10.1016/j.oraloncology.2014.04.008 .
doi: 10.1016/j.oraloncology.2014.04.008 pubmed: 24856188
Cros J, Sbidian E, Hans S, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol. 2013;24:2624–9. https://doi.org/10.1093/annonc/mdt338 .
doi: 10.1093/annonc/mdt338 pubmed: 23933559
Clauditz TS, Reiff M, Gravert L, et al. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology. 2011;43:459–64. https://doi.org/10.1097/PAT.0b013e3283484a60 .
doi: 10.1097/PAT.0b013e3283484a60 pubmed: 21670724
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitory therapy. Nat Rev Clin Oncol. 2018;15:7370747. https://doi.org/10.1038/s41571-018-0113-0 .
doi: 10.1038/s41571-018-0113-0
Takeda M, Sakai K, Terashima M, et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol. 2015;26:2477–82. https://doi.org/10.1093/annonc/mdv475 .
doi: 10.1093/annonc/mdv475 pubmed: 26420428
Kyoto University Human Genetic Variation Database. https://www.hgvd.genome.med.kyoto-u.ac.jp . Accessed 26 March 2021.
Narahara M, Higasa K, Nakamura S, et al. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. PLoS One. 2014;9:e100924. https://doi.org/10.1371/journal.pone.0100924 (eCollection 2014).
doi: 10.1371/journal.pone.0100924 pubmed: 24956270 pmcid: 4067418
Gevensleben H, Garcia-Murillas I, Graeser MK, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res. 2013;19:3276–84. https://doi.org/10.1158/1078-0432.CCR-12-3768 .
doi: 10.1158/1078-0432.CCR-12-3768 pubmed: 23637122 pmcid: 6485473
Alberts DS, Manning MR, Coulthard SW, et al. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer. 1981;47:645–8. https://doi.org/10.1002/1097-0142(19810215)47:4%3c645::aid-cncr2820470404%3e3.0.co;2-a .
doi: 10.1002/1097-0142(19810215)47:4<645::aid-cncr2820470404>3.0.co;2-a pubmed: 7194729
Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95:165–70. https://doi.org/10.1177/019459988609500206 .
doi: 10.1177/019459988609500206 pubmed: 3035459
Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol. 1988;16:197–202. https://doi.org/10.1002/mpo.2950160309 .
doi: 10.1002/mpo.2950160309 pubmed: 2837623
Dreyfuss AI, Clark JR, Fallon BG, et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60:2869–72. https://doi.org/10.1002/1097-0142(19871215)60:12%3c2869::aid-cncr2820601203%3e3.0.co;2-y .
doi: 10.1002/1097-0142(19871215)60:12<2869::aid-cncr2820601203>3.0.co;2-y pubmed: 2824016
Creagan ET, Woods JE, Schaid DJ, et al. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988;62:2313–9. https://doi.org/10.1002/1097-0142(19881201)62:11%3c2313::aid-cncr2820621110%3e3.0.co;2-4 .
doi: 10.1002/1097-0142(19881201)62:11<2313::aid-cncr2820621110>3.0.co;2-4 pubmed: 3179947
Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29:979–84. https://doi.org/10.1093/annonc/mdx771 .
doi: 10.1093/annonc/mdx771 pubmed: 29211833
Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30:1821–30. https://doi.org/10.1093/annonc/mdz291 .
doi: 10.1093/annonc/mdz291 pubmed: 31504139 pmcid: 6927318
Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020;31:412–21. https://doi.org/10.1016/j.annonc.2019.11.018 .
doi: 10.1016/j.annonc.2019.11.018 pubmed: 32067683
Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125–34. https://doi.org/10.1200/JCO.18.00545 .
doi: 10.1200/JCO.18.00545 pubmed: 30452336
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9. https://doi.org/10.1056/NEJMoa1714448 .
doi: 10.1056/NEJMoa1714448 pubmed: 29466156 pmcid: 29466156
Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–82. https://doi.org/10.1016/S1470-2045(19)30691-6 .
doi: 10.1016/S1470-2045(19)30691-6 pubmed: 31838007
Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37:1529–37. https://doi.org/10.1200/JCO.18.01859 .
doi: 10.1200/JCO.18.01859 pubmed: 30939095 pmcid: 6599407
Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 2015;26:1401–8. https://doi.org/10.1093/annonc/mdv190 .
doi: 10.1093/annonc/mdv190 pubmed: 25908605 pmcid: 4478975
Nomura H, Aoki D, Takahashi F, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol. 2011;22:636–42. https://doi.org/10.1093/annonc/mdq401 .
doi: 10.1093/annonc/mdq401 pubmed: 20696677
Aoki D, Watanabe Y, Jobo T, et al. Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer. Anticancer Res. 2009;29:561–6.
pubmed: 19331203
Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci. 2015;106:497–504. https://doi.org/10.1111/cas.12647 .
doi: 10.1111/cas.12647 pubmed: 25728850 pmcid: 4452149
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212.
doi: 10.1200/JCO.2015.62.3488
Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005;23:585–90. https://doi.org/10.1200/JCO.2005.06.125 .
doi: 10.1200/JCO.2005.06.125 pubmed: 15659505
Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43:33–6. https://doi.org/10.1016/j.oraloncology.2005.12.026 .
doi: 10.1016/j.oraloncology.2005.12.026 pubmed: 16757202

Auteurs

Yoshinori Imamura (Y)

Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Kaoru Tanaka (K)

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Naomi Kiyota (N)

Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. nkiyota@med.kobe-u.ac.jp.
Cancer Center, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. nkiyota@med.kobe-u.ac.jp.
ORCID: 0000-0001-8021-6116

Hidetoshi Hayashi (H)

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Ichiro Ota (I)

Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.

Akihito Arai (A)

Department of Otolaryngology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji Kamigyo-ku, Kyoto, 602-8566, Japan.

Shigemichi Iwae (S)

Department of Head and Neck Surgery, Hyogo Cancer Center, 13-70 Kitaoujicho, Akashi, Hyogo, 673-8588, Japan.

Shujiro Minami (S)

Department of Otolaryngology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.

Katsunari Yane (K)

Department of Otolaryngology, Kindai University Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara, 630-0293, Japan.

Tomoko Yamazaki (T)

Division of Head and Neck Medical Oncology, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiode, Natori, Miyagi, 981-1293, Japan.

Yoshiaki Nagatani (Y)

Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Masanori Toyoda (M)

Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Takayuki Takahama (T)

Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Kazuko Sakai (K)

Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Kazuto Nishio (K)

Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Naoki Otsuki (N)

Department of Otolaryngology-Head and Neck Surgery, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Ken-Ichi Nibu (KI)

Department of Otolaryngology-Head and Neck Surgery, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Hironobu Minami (H)

Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Cancer Center, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à activité tyrosine kinase › Kinase du lymphome anaplasique › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Docetaxel › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Docetaxel plus cisplatin in recurrent and/or...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Docetaxel plus cisplatin in recurrent and/or...